Effect of sofosbuvir-based DAAs on changes in lower-density lipoprotein in HCV patients: a systematic review and meta-analysis

Table 3 Sensitivity analysis using leave-one-out method for changes in low-density lipoprotein

First author (publication year)	Statistics with study removed
First author (publication year)	Difference in means	Lower limit	Upper limit	Z-value	P-value
Sofosbuvir-based vs. non-sofosbuvir direct anti-viral agents
Week 4
Özdoğan (2020)	13.43	5.55	21.30	3.34	0.001
Inoue (2018)	14.79	6.75	22.84	3.60	< 0.001
Endo (2017)	11.54	3.76	19.33	2.91	0.004
Kan (2017)	11.93	4.20	19.66	3.02	0.002
Notsumata (2017)	14.39	5.76	23.02	3.27	0.001
Hashimoto (2016)	9.82	3.96	15.68	3.28	0.001
End of treatment
Özdoğan (2020)	7.98	− 0.35	16.32	1.88	0.060
Inoue (2018)	10.41	4.51	16.32	3.45	0.001
Endo (2017)	3.93	− 4.16	12.01	0.95	0.341
Notsumata (2017)	5.62	− 6.54	17.77	0.91	0.365
Post-treatment week 12
Inoue (2018)	− 2.61	− 13.47	8.24	− 0.47	0.637
Endo (2017)	− 3.41	− 15.62	8.80	− 0.55	0.584
Notsumata (2017)	− 9.27	− 14.11	− 4.42	− 3.75	< 0.001
Post-treatment week 24
Özdoğan (2020)	− 7.12	− 21.19	6.94	− 0.99	0.321
Inoue (2018)	− 0.21	− 4.44	4.02	− 0.10	0.921
Notsumata (2017)	− 8.42	− 22.27	5.42	− 1.19	0.233
Sofosbuvir/ledipasvir vs. asunaprevir/daclatasvir
Week 4
Inoue (2018)	18.78	14.60	22.95	8.81	< 0.001
Endo (2017)	17.65	13.11	22.19	7.62	< 0.001
Notsumata (2017)	18.03	13.19	22.87	7.31	< 0.001
Hashimoto (2016)	16.12	12.06	20.18	7.78	< 0.001
End of treatment
Inoue (2018)	18.49	13.15	23.82	6.79	< 0.001
Endo (2017)	13.92	− 0.75	28.60	1.86	0.063
Notsumata (2017)	11.31	2.02	20.60	2.39	0.017
Post-treatment week 12
Inoue (2018)	− 1.75	− 14.81	11.32	− 0.26	0.793
Endo (2017)	− 3.77	− 21.01	13.47	− 0.43	0.668
Notsumata (2017)	− 10.33	− 15.74	− 4.91	− 3.74	< 0.001

ISSN: 1471-2334